Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
CA 2291338 A1 · Owner: The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy · Inventors: Kirk, Allan D.; Knechtle, Stuart J.; Harlan, David M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method is provided for preventing and reversing acute allograft rejection wherein both the CD80/CD86:CD28/CTLA-4 interaction and the CD40:CD154 interaction are interrupted. The effect of the method on treating autoimmune diseases and allergy is also set forth.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 10, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.